SCHEMBL3325784

SCHEMBL3325784

NC[C@H]1CN(c2ccc(Br)cn2)C(=O)O1

nearest known ligand 0.47

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 7/20 0.46
F10 P00742 1/20 0.44
AKR1C3 P42330 1/20 0.38
GRM2 Q14416 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL8354006 0.99 GRM5 (0.45) GRM5F10AKR1C3GRM2
SCHEMBL15856197 0.88 MAOA (0.47) GRM5AKR1C3
SCHEMBL3327072 0.88 MAOA (0.47) GRM5AKR1C3
SCHEMBL15856168 0.88 MAOA (0.47) GRM5AKR1C3
SCHEMBL17286803 0.86 GRM5 (0.48) GRM5AKR1C3GRM2
SCHEMBL17286801 0.86 GRM5 (0.48) GRM5AKR1C3GRM2
SCHEMBL15856178 0.86 GRM5 (0.46) GRM5F10AKR1C3GRM2
SCHEMBL2835182 0.84 GRM5 (0.46) GRM5F10GRM2
SCHEMBL2835414 0.84 GRM5 (0.46) GRM5F10GRM2
SCHEMBL2835819 0.84 GRM5 (0.46) GRM5F10GRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137243-A1 Oxazolidinone And/Or Isoxazoline As Antibacterial Agents ASTRAZENECA AB (SE) 2010-06-03 US disclosed
US-20100137243-A1 Oxazolidinone And/Or Isoxazoline As Antibacterial Agents ASTRAZENECA AB (SE) 2010-06-03 US disclosed
US-20100137243-A1 Oxazolidinone And/Or Isoxazoline As Antibacterial Agents ASTRAZENECA AB (SE) 2010-06-03 US disclosed
US-7396847-B2 Oxazolidinone and/or isoxazoline as antibacterial agents ASTRAZENECA AB (SE) 2008-07-08 US disclosed
US-7396847-B2 Oxazolidinone and/or isoxazoline as antibacterial agents ASTRAZENECA AB (SE) 2008-07-08 US disclosed
US-7396847-B2 Oxazolidinone and/or isoxazoline as antibacterial agents ASTRAZENECA AB (SE) 2008-07-08 US disclosed
EP-1427711-B1 OXAZOLIDINONE AND/OR ISOXAZOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS ASTRAZENECA AB (SE) 2005-07-13 EP disclosed
US-20050107435-A1 Oxazolidinone and/or isoxazoline as antibacterial agents ASTRAZENECA AB (SE) 2005-05-19 US disclosed
EP-1427711-A1 OXAZOLIDINONE AND/OR ISOXAZOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS AstraZeneca AB (SE) 2004-06-16 EP disclosed
WO-2003022824-A1 OXAZOLIDINONE AND/OR ISOXAZOLINE AS ANTIBACTERIAL AGENTS ASTRAZENECA AB (SE) 2003-03-20 WO disclosed
EP-0789025-B1 Substituted oxazolidinone and their use as antibacterial medicine BAYER AG (DE) 2001-04-04 EP disclosed
EP-0789025-A1 Substituted oxazolidinone and their use as antibacterial medicine BAYER AG (DE) 1997-08-13 EP disclosed
EP-0789026-A1 Hetero-aryl oxazolidinone and their use as antibacterial medicine BAYER AG (DE) 1997-08-13 EP disclosed
EP-0694543-A1 6-membered N-heteroaryloxazolidinones BAYER AG (DE) 1996-01-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137243-A1 Oxazolidinone And/Or Isoxazoline As Antibacterial Agents CYP8B1, HRH2, CYP2W1 GRM5 2992/4885F10 1208/4885AKR1C3 1597/4885
US-20050107435-A1 Oxazolidinone and/or isoxazoline as antibacterial agents CYP8B1, CYP2W1, HRH2 GRM5 2838/4885F10 1659/4885AKR1C3 1882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.